These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31735504)

  • 1. Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes.
    Smatti MK; Nasrallah GK; Al Thani AA; Yassine HM
    Vaccine; 2020 Jan; 38(4):815-821. PubMed ID: 31735504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection.
    Yassine HM; Boyington JC; McTamney PM; Wei CJ; Kanekiyo M; Kong WP; Gallagher JR; Wang L; Zhang Y; Joyce MG; Lingwood D; Moin SM; Andersen H; Okuno Y; Rao SS; Harris AK; Kwong PD; Mascola JR; Nabel GJ; Graham BS
    Nat Med; 2015 Sep; 21(9):1065-70. PubMed ID: 26301691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of H7N9 hemagglutinin novel protein epitopes that elicit strong antibody-dependent, cell-mediated cytotoxic activities with protection from influenza infection in mouse model.
    Zhu P; Yi X; Zhang L; Liu Y; Wang S; Gu J; Zhu X; Yu X
    Cell Immunol; 2021 Jan; 359():104255. PubMed ID: 33316647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.
    Yassine HM; McTamney PM; Boyington JC; Ruckwardt TJ; Crank MC; Smatti MK; Ledgerwood JE; Graham BS
    Sci Rep; 2018 Jun; 8(1):8628. PubMed ID: 29872070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.
    de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF
    Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris.
    Wang SC; Liao HY; Zhang JY; Cheng TR; Wong CH
    Virology; 2019 Jan; 526():125-137. PubMed ID: 30388628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.
    Impagliazzo A; Milder F; Kuipers H; Wagner MV; Zhu X; Hoffman RM; van Meersbergen R; Huizingh J; Wanningen P; Verspuij J; de Man M; Ding Z; Apetri A; Kükrer B; Sneekes-Vriese E; Tomkiewicz D; Laursen NS; Lee PS; Zakrzewska A; Dekking L; Tolboom J; Tettero L; van Meerten S; Yu W; Koudstaal W; Goudsmit J; Ward AB; Meijberg W; Wilson IA; Radošević K
    Science; 2015 Sep; 349(6254):1301-6. PubMed ID: 26303961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.
    Whittle JR; Wheatley AK; Wu L; Lingwood D; Kanekiyo M; Ma SS; Narpala SR; Yassine HM; Frank GM; Yewdell JW; Ledgerwood JE; Wei CJ; McDermott AB; Graham BS; Koup RA; Nabel GJ
    J Virol; 2014 Apr; 88(8):4047-57. PubMed ID: 24501410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
    Ellebedy AH; Krammer F; Li GM; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R; Edupuganti S; Spearman P; Andrews SF; Wilson PC; García-Sastre A; Mulligan MJ; Mehta AK; Palese P; Ahmed R
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13133-8. PubMed ID: 25157133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
    Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
    mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.